Tja, MLNM, die 6 Dollar waren die Punktlandung ruhrpottzocker.
Gruss E.
FDA Accepts For Review NDA Filing Of VELCADE
Monday, March 10, 2003 11:18 AM ET Printer-friendly version
CAMBRIDGE, Mass. -(Dow Jones)- Millennium Pharmaceuticals Inc. (MLNM, news) said the U.S. Food and Drug Administration granted priority review designation to its new drug application for Velcade, a treatment for relapsed and refractory multiple myeloma, which is a type of bone marrow cancer.
Priority review is granted to a company seeking approval for a new treatment that addresses an unmet medical need. Under this type of application process, the review period is reduced from 10 to six months.
In a press release Monday, Millennium noted that the acceptance of the filing comes about six weeks after it filed marketing applications with the U.S. and European Union. The FDA granted fast-track status to Velcade in June 2002, while the Agency for the Evaluation of Medicinal Products in Europe accepted the company's marketing application for review on Feb. 24.
Shares of Millennium Pharmaceuticals climbed about 11% to $7.78 on Nasdaq volume of 5.8 million shares. Average daily volume is 4.9 million shares.
Company Web site: http://www.millennium.com
-Thomas Derpinghaus; Dow Jones Newswires; 201-938-5388
|
